This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Rozanolixizumab
- DrugBank Accession Number
- DB14919
- Background
Rozanolixizumab is under investigation in clinical trial NCT03861481 (A Study to Assess the Efficacy, Safety and Tolerability of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy).
- Type
- Biotech
- Groups
- Investigational
- Synonyms
- Rozanolixizumab
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbatacept The risk or severity of adverse effects can be increased when Abatacept is combined with Rozanolixizumab. Abciximab The risk or severity of adverse effects can be increased when Abciximab is combined with Rozanolixizumab. Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Rozanolixizumab. Adenovirus type 7 vaccine live The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Rozanolixizumab. Aducanumab The risk or severity of adverse effects can be increased when Aducanumab is combined with Rozanolixizumab. Aldesleukin The risk or severity of adverse effects can be increased when Aldesleukin is combined with Rozanolixizumab. Alefacept The risk or severity of adverse effects can be increased when Alefacept is combined with Rozanolixizumab. Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Rozanolixizumab. Alirocumab The risk or severity of adverse effects can be increased when Alirocumab is combined with Rozanolixizumab. Allogeneic processed thymus tissue The therapeutic efficacy of Allogeneic processed thymus tissue can be decreased when used in combination with Rozanolixizumab. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Not Available
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- P7186074QC
- CAS number
- 1584645-37-3
References
- General References
- Not Available
- External Links
- Not Available
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Active Not Recruiting Treatment Myasthenia Gravis, Generalized 1 3 Completed Treatment Myasthenia Gravis, Generalized 2 3 Enrolling by Invitation Treatment Primary Immune Thrombocytopenia (ITP) 1 3 Recruiting Treatment Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOG-AD) 1 3 Recruiting Treatment Primary Immune Thrombocytopenia (ITP) 2 2 Completed Treatment Chronic Inflammatory Demyelinating Polyradiculoneuropathy 2 2 Completed Treatment Myasthenia Gravis 1 2 Recruiting Treatment Leucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis 1 1 Completed Basic Science Healthy Study Participants 1 1 Completed Basic Science Healthy Subjects (HS) 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created at May 20, 2019 14:35 / Updated at February 21, 2021 18:55